Overview
NEX Health Intelligence develops predictive tools for hospital infection risk, focused on forecasting where drug-resistant infections could spread next inside care facilities. Its target market is hospitals and healthcare operators seeking earlier visibility into antimicrobial-resistance risks and infection-control priorities. The company’s stated differentiation is its narrow focus on spread prediction for drug-resistant infections within hospitals, rather than broad clinical analytics. NEX raised a €1M pre-seed round announced in May 2026, positioning the company at an early stage of product and market development.
Funding History
Exclusive: NEX Health Intelligence lands €1M to predict where drug-resistant infections will spread next inside hospitals
Frequently Asked Questions
- How much funding does AI Funding track for NEX Health Intelligence?
- AI Funding tracks €1M for NEX Health Intelligence across 1 funding round in this database.
- Who are NEX Health Intelligence's investors?
- NEX Health Intelligence's investors include Brighteye Ventures.
- What does NEX Health Intelligence do?
- NEX Health Intelligence develops predictive tools for hospital infection risk, focused on forecasting where drug-resistant infections could spread next inside care facilities. Its target market is hospitals and healthcare operators seeking earlier visibility into antimicrobial-resistance risks and infection-control priorities. The company’s stated differentiation is its narrow focus on spread prediction for drug-resistant infections within hospitals, rather than broad clinical analytics. NEX raised a €1M pre-seed round announced in May 2026, positioning the company at an early stage of product and market development.
- Where is NEX Health Intelligence headquartered?
- NEX Health Intelligence is headquartered in San Francisco, CA.
Investors
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.